In this ERN Rare-Liver webinar, held on 11 April 2023, the Dr Reiberger  and Dr Burghart discuss about the evidence of cirrhosis and portal hypertension in Wilson Disease and share their experience as physicians as well as what are the therapeutic aspects such as the impact of chelator-therapy on acute and chronic liver disease progression and portal hypertension targeted therapy.

Targeted Audience

  • General practitioners
  • Hepatologists
  • Oncologists
  • Health care professionals

Portal hypertension (CPSH) in Wilson Disease



Thomas Reiberger Thomas Reiberger coordinates the Vienna Rare Liver Disease (RALID) center at the Vienna General Hospital, an affiliated member of the European Reference Network (ERN RARE LIVER). As a Professor of Hepatology he is heading the Liver Outpatient Clinic and runs a Laboratory for Portal Hypertension and Liver Fibrosis at the Medical University of Vienna. His translational research focuses on hemodynamic and structural characteristics of advanced chronic liver disease as well as diagnostic and prognostic biomarkers and extends to patients with rare liver diseases.
Lukas Burghart Lukas Burghart is a GI resident at the Vienna-Ottakring municipal hospital associated with the Medical University of Vienna, where he is inscribed in the clinical PhD program. Dr. Burghart is part of the research group of Prof. Thomas Reiberger, and his PhD projects focus on the development of portal hypertension and the prognostic impact of clinically significant portal hypertension in patients with rare liver diseases.